Kirin Holdings Compa (KNBWY) 13.2200 $KNBWY
Investigation Report on China's Epoetin Alfa Market
M2 - Tue Mar 11, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rt9tv/investigation) has announced the addition of the "Investigation Report on China Epoetin Alfa Market, 2009-2018" report to their offering. Epoetin alfa refers to erythropoietin (EPO), a hormone-like substance secreted by kidney and liver that stimulates erythropoiesis. Indications of EPO approved in China are renal anemia, anemia after chemotherapy and surgery perioperative red blood cell mobilization. The ratio between EPO used in renal dialysis and in chemotherapy is 3:1. Growth rate of EPO used in chemotherapy is about 20% to 25%, which is higher than that of renal dialysis. However, in the international market, more EPO is used in anemia after chemotherapy than in renal dialysis. This indicates huge market space for EPO used in anemia after chemotherapy in China. Originally developed by Amgen Inc., epoetin alfa was approved to the U.S. in June 1989 by FDA with the trade name ""Epogen"". It is sold in over 40 countries now. Amgen is the only authorized product sold in the U.S. hemodialysis market. However, in other indications' market in the U.S., due to financial shortage, Amgen gave the marketing right of Epogen to Kirin-Amgen, Inc. (joint venture of Amgen and Kirin). The company then authorized Ortho Pharmaceutical Corporation of Johnson & Johnson to sell the product with the brand name ""Procrit"". In other countries including Chinese mainland, Taiwan and Japan, the drug is sold by Kirin Inc. and Johnson & Johnson with the trade names ""Espo"" and ""Eprex"" respectively. Both the companies are authorized by Kirin-Amgen. Key Topics Covered: 1 Relevant Concepts of Epoetin Alfa 2 Market Overview of Epoetin Alfa in China 3 Investigation on Sales Value of Epoetin Alfa in China, 2009-2013 4 Investigation on Market Share of Major Epoetin Alfa Manufacturers in China, 2009-2013 5 Investigation on Market Size of Epoetin Alfa by Dosage Form in China, 2009-2013 6 Reference Price of Epoetin Alfa Produced by Different Enterprises in China Hospital Market 7 Analysis on Major Epoetin Alfa Manufacturers in China, 2009-2013 8 Prospect of China Epoetin Alfa Market, 2014-2018 Companies Mentioned - Shenyang Sunshine Pharmaceutical Co., Ltd. - Kirin Brewery Company, Limited - NCPC GeneTech Biotechnology development Co., Ltd. - Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. - Beijing Sihuan Biopharmaceutical Co., Ltd. - Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd. - Harbin Pharmaceutical Group Bio-Engineering Co., Ltd. - Shandong Kexing Bioproducts Co., Ltd. For more information visit http://www.researchandmarkets.com/research/5r...estigation
Mitsubishi Corporation acquires Kirin Holdings' Food Science Business
JCN Newswire - Mon Mar 18, 9:56PM CDT
Kirin Holdings Company, Limited (KH) and Mitsubishi Corporation (MC) are pleased to announce that they have entered into a share transfer agreement, whereby all shares of KH's food science subsidiary, Kirin Kyowa Foods Company, Limited (KKF), will be transferred to MC. MC will purchase about 81% of KKF shares in July 2013 and the remainder in January 2015.
Investigation Report on China's Epoetin Alfa Market
M2 - Tue Mar 11, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rt9tv/investigation) has announced the addition of the "Investigation Report on China Epoetin Alfa Market, 2009-2018" report to their offering. Epoetin alfa refers to erythropoietin (EPO), a hormone-like substance secreted by kidney and liver that stimulates erythropoiesis. Indications of EPO approved in China are renal anemia, anemia after chemotherapy and surgery perioperative red blood cell mobilization. The ratio between EPO used in renal dialysis and in chemotherapy is 3:1. Growth rate of EPO used in chemotherapy is about 20% to 25%, which is higher than that of renal dialysis. However, in the international market, more EPO is used in anemia after chemotherapy than in renal dialysis. This indicates huge market space for EPO used in anemia after chemotherapy in China. Originally developed by Amgen Inc., epoetin alfa was approved to the U.S. in June 1989 by FDA with the trade name ""Epogen"". It is sold in over 40 countries now. Amgen is the only authorized product sold in the U.S. hemodialysis market. However, in other indications' market in the U.S., due to financial shortage, Amgen gave the marketing right of Epogen to Kirin-Amgen, Inc. (joint venture of Amgen and Kirin). The company then authorized Ortho Pharmaceutical Corporation of Johnson & Johnson to sell the product with the brand name ""Procrit"". In other countries including Chinese mainland, Taiwan and Japan, the drug is sold by Kirin Inc. and Johnson & Johnson with the trade names ""Espo"" and ""Eprex"" respectively. Both the companies are authorized by Kirin-Amgen. Key Topics Covered: 1 Relevant Concepts of Epoetin Alfa 2 Market Overview of Epoetin Alfa in China 3 Investigation on Sales Value of Epoetin Alfa in China, 2009-2013 4 Investigation on Market Share of Major Epoetin Alfa Manufacturers in China, 2009-2013 5 Investigation on Market Size of Epoetin Alfa by Dosage Form in China, 2009-2013 6 Reference Price of Epoetin Alfa Produced by Different Enterprises in China Hospital Market 7 Analysis on Major Epoetin Alfa Manufacturers in China, 2009-2013 8 Prospect of China Epoetin Alfa Market, 2014-2018 Companies Mentioned - Shenyang Sunshine Pharmaceutical Co., Ltd. - Kirin Brewery Company, Limited - NCPC GeneTech Biotechnology development Co., Ltd. - Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. - Beijing Sihuan Biopharmaceutical Co., Ltd. - Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd. - Harbin Pharmaceutical Group Bio-Engineering Co., Ltd. - Shandong Kexing Bioproducts Co., Ltd. For more information visit http://www.researchandmarkets.com/research/5r...estigation
Mitsubishi Corporation acquires Kirin Holdings' Food Science Business
JCN Newswire - Mon Mar 18, 9:56PM CDT
Kirin Holdings Company, Limited (KH) and Mitsubishi Corporation (MC) are pleased to announce that they have entered into a share transfer agreement, whereby all shares of KH's food science subsidiary, Kirin Kyowa Foods Company, Limited (KKF), will be transferred to MC. MC will purchase about 81% of KKF shares in July 2013 and the remainder in January 2015.
